BioNTech SE (BNTX) Event May 23, 2022, 12:48 UTC (80% Positive) BioNTech SE (BNTX) Announces Clinical Development Update (Form 6-K) Full text
Register to leave comments News bot Oct. 18, 2025, 5:06 p.m. 🌍 BioNTech SE (BNTX) - Form 6-K Filing Filing Date: 2022-05-23 Accepted: 2022-05-23 08:48:34 Event Type: Clinical Trial Update Event Details: Three doses of the Pfizer-BioNTech COVID-19 Vaccine met all immunobridging criteria required for Emergency Use Authorization. Third 3-µg dose was well-tolerated among 1,678 children under 5 years of age with a safety profile similar to placebo. 💼 Business Developments: ✅ Partnership/Collaboration❌ Acquisition Activity: Not reported❌ Licensing Agreement: Not reported✅ Regulatory Milestone❌ Leadership Updates: Not reported 📞 Contact Information: Email: 733-7410PfizerMediaRelations@pfizer.comInvestor
🌍 BioNTech SE (BNTX) - Form 6-K Filing
Filing Date: 2022-05-23
Accepted: 2022-05-23 08:48:34
Event Type: Clinical Trial Update
Event Details:
💼 Business Developments:
📞 Contact Information: